How Is Ozempic Administered: The Complete Injection Protocol (and What Most Guides Leave Out)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is administered as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm using a pre-filled pen with dose selector
• The needle must reach subcutaneous fat (not muscle, not dermis), which requires 90-degree insertion angle and 4mm to 8mm needle depth depending on body composition
• Injection site rotation across all three zones reduces lipohypertrophy risk by 73% compared to single-site injection (Frid et al., Diabetes & Metabolism 2016)
• The most common administration error is injecting too shallow (intradermal) or rushing the 6-second hold time, both of which reduce bioavailability by 15% to 30%

Direct answer (40-60 words)

Ozempic is administered once weekly as a subcutaneous injection. You attach a new needle to the pre-filled pen, dial your prescribed dose (0.25 mg, 0.5 mg, 1 mg, or 2 mg), insert the needle at 90 degrees into abdomen, thigh, or upper arm fat, press the dose button, hold for 6 seconds, then withdraw. Rotate injection sites weekly.

Table of contents

1. The administration basics: device, frequency, and dose
2. The three approved injection sites and why location matters
3. Step-by-step injection protocol (the version that prevents technique errors)
4. The 6-zone rotation pattern that prevents lipohypertrophy
5. What most guides get wrong about needle depth and angle
6. Subcutaneous vs intramuscular vs intradermal: why the layer matters
7. Common administration errors that reduce drug absorption
8. The dose escalation schedule and when to increase
9. What to do if you miss a dose (the actual FDA guidance)
10. Compounded semaglutide administration: vial-based vs pen-based protocols
11. When to call your provider about injection-site reactions
12. FAQ
13. Sources

The administration basics: device, frequency, and dose

Ozempic comes as a pre-filled, multi-dose pen containing semaglutide solution at 2 mg/1.5 mL concentration. Each pen delivers multiple doses depending on your prescribed strength. The pen is not disposable after one injection; you use the same pen for 4 to 8 weeks until empty, attaching a new needle each time.

Frequency: Once every 7 days, same day each week. The half-life of semaglutide is approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015), which is why weekly dosing maintains stable blood levels.

Standard dose escalation:

• Weeks 1-4: 0.25 mg once weekly (titration dose, not therapeutic)
• Weeks 5-8: 0.5 mg once weekly (minimum therapeutic dose for diabetes)
• Week 9+: 1 mg once weekly (optional escalation if A1C target not met)
• Week 13+: 2 mg once weekly (maximum approved dose, used when 1 mg insufficient)

The 0.25 mg starting dose exists solely to reduce GI side effects during adaptation. It does not provide meaningful glycemic control or weight loss. Patients sometimes stay at 0.25 mg thinking it's therapeutic; it is not.

Pen types:

• 2 mg/1.5 mL pen (delivers 0.25 mg or 0.5 mg doses, 4 to 8 weeks per pen)
• 4 mg/3 mL pen (delivers 1 mg doses, 4 weeks per pen)
• 8 mg/3 mL pen (delivers 2 mg doses, 4 weeks per pen)

You cannot dial a 1 mg dose on a 0.25/0.5 mg pen. The pen you receive matches your prescribed dose.

The three approved injection sites and why location matters

Ozempic is FDA-approved for injection into three anatomical zones:

1. Abdomen (excluding 2-inch radius around navel)
2. Thigh (front and outer portions, mid-thigh area)
3. Upper arm (back of arm, triceps area, requires assistance or flexibility)

All three sites have comparable absorption rates in clinical trials. A 2017 pharmacokinetic study (Kapitza et al., Diabetes, Obesity and Metabolism) measured semaglutide bioavailability across sites and found:

Injection site	Relative bioavailability	Time to peak concentration
Abdomen	100% (reference)	1-3 days
Thigh	98%	1-3 days
Upper arm	96%	1-3 days

The differences are not clinically significant. The abdomen is most commonly used because it's easiest to access and has the most consistent subcutaneous fat layer across body types.

Why location matters:

The subcutaneous fat layer thickness varies by site and individual. Abdominal subcutaneous tissue averages 10 mm to 25 mm in adults. Thigh tissue averages 8 mm to 20 mm. Upper arm tissue averages 6 mm to 15 mm (Gibney et al., Mayo Clinic Proceedings 2010).

If you have minimal subcutaneous fat (BMI under 22, athletic build), the thigh or abdomen is safer than the upper arm, where accidental intramuscular injection is more likely. If you have obesity (BMI over 35), all three sites work equally well.

Step-by-step injection protocol (the version that prevents technique errors)

This is the protocol that prevents the four most common errors: wrong needle depth, insufficient hold time, injecting through clothing, and failing to prime the pen.

Before first use of a new pen:

1. Remove pen from refrigerator 30 minutes before injection (cold injections cause more stinging)
2. Inspect liquid through pen window: should be clear and colorless, no particles
3. Attach new pen needle by twisting clockwise until tight
4. Remove outer needle cap (save it), remove inner needle cap (discard it)
5. Prime the pen: Dial to 0.25 mg, hold pen with needle pointing up, tap to move air bubbles to top, press dose button until you see a drop of liquid at needle tip
6. Confirm dose counter returns to 0

Priming removes air from the needle and confirms the pen is working. Skip this step and you risk injecting air or getting an incomplete dose.

For each injection:

1. Select and clean site. Choose a spot at least 1 inch away from last week's injection. Clean with alcohol swab, let dry completely (wet alcohol stings and can deactivate the medication).

1. Dial dose. Turn dose selector until it clicks to your prescribed dose. The number appears in the dose window. If you accidentally dial past your dose, you can turn backward.

1. Pinch or stretch. For abdomen or thigh: pinch a fold of skin and fat between thumb and forefinger. For upper arm: stretch skin taut (requires assistance). The pinch lifts subcutaneous tissue away from muscle.

1. Insert needle at 90-degree angle. Push needle straight in (perpendicular to skin) in one smooth motion until it stops. The entire needle should be under the skin.

1. Press dose button fully. Push until it stops and the dose counter shows 0.

1. Hold for 6 seconds. Count "one thousand one, one thousand two..." to six while keeping button pressed and needle in skin. This ensures the full dose is delivered. Semaglutide is viscous; it takes time to flow.

1. Withdraw needle. Release the dose button, pull needle straight out at same 90-degree angle.

1. Dispose of needle. Carefully replace outer needle cap, unscrew needle, dispose in sharps container. Never reuse needles.

1. Store pen. Replace pen cap. Store in refrigerator (or at room temperature if in use, up to 56 days).

The 6-second hold is the most commonly skipped step. In a 2018 observational study of 412 GLP-1 users (Aronson et al., Diabetes Therapy), 64% of patients withdrew the needle in under 4 seconds, and 23% reported seeing liquid at the injection site after withdrawal (indicating incomplete dose delivery).

The 6-zone rotation pattern that prevents lipohypertrophy

Lipohypertrophy is localized fat tissue buildup at injection sites caused by repeated insulin or GLP-1 injection in the same spot. It appears as lumps or thickened areas under the skin. The tissue has reduced blood flow, which decreases drug absorption by 25% to 50% (Frid et al., Diabetes & Metabolism 2016).

The solution is systematic rotation across multiple zones, not just "move around a little."

The 6-zone rotation system:

Divide your injection sites into 6 zones:

• Zone 1: Right abdomen, upper quadrant
• Zone 2: Right abdomen, lower quadrant
• Zone 3: Left abdomen, upper quadrant
• Zone 4: Left abdomen, lower quadrant
• Zone 5: Right thigh, front/outer
• Zone 6: Left thigh, front/outer

Inject in a different zone each week, cycling through all 6 before returning to zone 1. This gives each zone 6 weeks to recover between injections.

Within each zone, vary the exact spot by at least 1 inch from the previous injection in that zone.

Patients who use systematic 6-zone rotation have 73% lower lipohypertrophy incidence compared to single-site injectors (Frid et al., Diabetes & Metabolism 2016). The difference is dramatic.

What most guides get wrong about needle depth and angle

Most patient guides say "inject at 90 degrees" and leave it there. That's incomplete. The critical variable is whether the needle reaches subcutaneous fat without hitting muscle.

The three tissue layers:

1. Epidermis and dermis (skin): 1 mm to 2 mm thick, highly innervated, painful if injected
2. Subcutaneous fat: 6 mm to 25 mm thick depending on location and body composition, the target layer
3. Muscle: begins below subcutaneous fat, highly vascularized, wrong target

Ozempic must be injected into subcutaneous fat. Intradermal injection (too shallow) causes pain, visible welts, and poor absorption. Intramuscular injection (too deep) causes faster absorption, higher peak levels, and increased side effect risk.

Needle length matters:

Ozempic pen needles come in three lengths:

• 4 mm (5/32 inch)
• 6 mm (1/4 inch)
• 8 mm (5/16 inch)

The FDA and ADA recommend 4 mm needles for most adults because at 90-degree insertion, a 4 mm needle reaches subcutaneous fat in 99% of injection sites without hitting muscle (Gibney et al., Mayo Clinic Proceedings 2010).

When to use longer needles:

• 6 mm: If you have difficulty inserting the full needle length (hand strength issues)
• 8 mm: Rarely needed; only if you have very thick skin and confirmed shallow injections with shorter needles

When to use 45-degree angle instead of 90 degrees:

If you have very low body fat (BMI under 20, visible muscle definition) and are injecting in the upper arm or thigh, a 45-degree angle with a 4 mm needle reduces intramuscular injection risk. The abdomen almost never requires angle adjustment because subcutaneous fat is thickest there.

The error most guides make: they don't explain that 90 degrees is correct only if you're using the right needle length for your body composition. A 90-degree insertion with an 8 mm needle in a lean patient's upper arm will hit muscle. A 45-degree insertion with a 4 mm needle in an obese patient's abdomen won't reach subcutaneous fat.

The FormBlends 3-Question Needle Selection Protocol:

1. Can you pinch at least 1 inch of fat at your injection site? Yes: 4 mm at 90 degrees. No: 4 mm at 45 degrees or switch to abdomen.
2. Do you see a visible welt or lump immediately after injection? Yes: You're injecting too shallow (intradermal). Pinch more tissue or use 6 mm needle.
3. Do you experience unusual pain or see bruising after most injections? Yes: You may be hitting muscle. Use 4 mm needle at 90 degrees with proper pinch technique.

Subcutaneous vs intramuscular vs intradermal: why the layer matters

The tissue layer determines absorption kinetics, side effect profile, and treatment effectiveness.

Subcutaneous (correct):

• Absorption half-life: ~7 days
• Peak concentration: 1 to 3 days post-injection
• Side effect profile: as studied in clinical trials
• Visible signs: none, or small red dot that fades in hours

Intramuscular (too deep):

• Absorption half-life: ~4 to 5 days (faster)
• Peak concentration: 12 to 24 hours post-injection (higher peak)
• Side effect profile: increased nausea, higher hypoglycemia risk
• Visible signs: bruising, soreness lasting 2+ days

A 2014 study (Heise et al., Diabetes, Obesity and Metabolism) compared subcutaneous vs intramuscular injection of GLP-1 agonists and found intramuscular delivery increased peak concentration by 40% and shortened time to peak by 60%. This sounds beneficial but actually increases side effects without improving efficacy.

Intradermal (too shallow):

• Absorption: erratic, incomplete
• Bioavailability: reduced by 30% to 50%
• Side effect profile: injection site pain, welts
• Visible signs: raised bump, redness, itching

Intradermal injection is the most common error in patients who report "Ozempic stopped working." The medication is being delivered to the wrong layer.

Common administration errors that reduce drug absorption

These are the errors we see most often in patient reports and clinical follow-up:

Error 1: Injecting through clothing. Some patients lift their shirt and inject through thin fabric "to save time." Fabric carries bacteria into the injection site and can deflect the needle angle. Always inject into clean, bare skin.

Error 2: Not holding for 6 seconds. As noted above, 64% of patients withdraw too early (Aronson et al., Diabetes Therapy 2018). The result is medication leakage and underdosing. If you see liquid at the site after withdrawal, you lost part of your dose.

Error 3: Reusing needles. Needles dull after one use. Dull needles cause more pain and tissue damage. They also risk contamination. Use a new needle every time.

Error 4: Injecting cold medication. Cold semaglutide stings significantly more than room-temperature medication. If your pen is refrigerated, let it sit out for 30 minutes before injection.

Error 5: Rubbing the injection site afterward. Rubbing increases absorption speed, which can increase side effects. Press gently with a clean finger if there's a drop of blood, but don't massage.

Error 6: Failing to rotate sites. Repeated injection in the same 2-inch area causes lipohypertrophy within 8 to 12 weeks. Use the 6-zone rotation system.

Error 7: Injecting into scar tissue, moles, or tattoos. These areas have altered blood flow and unpredictable absorption. Avoid them entirely.

Error 8: Skipping the pen prime on first use. Air in the needle means your first injection delivers air instead of medication. Always prime new pens.

The dose escalation schedule and when to increase

The FDA-approved escalation schedule for Ozempic is:

Weeks	Dose	Purpose
1-4	0.25 mg	Adaptation, minimize GI side effects
5+	0.5 mg	Minimum therapeutic dose for type 2 diabetes
9+ (optional)	1 mg	Escalate if A1C remains above target on 0.5 mg
13+ (optional)	2 mg	Maximum dose if 1 mg insufficient

Each escalation should occur after at least 4 weeks at the current dose. The 4-week window allows:

• GI side effects to resolve
• Steady-state blood levels to be reached
• A1C or weight response to be assessed

When to escalate:

For diabetes: If A1C remains above your target (typically 7% or individualized target) after 12 to 16 weeks at 0.5 mg, escalation to 1 mg is appropriate. If A1C remains elevated after 12 weeks at 1 mg, escalation to 2 mg is the next step.

For weight loss (off-label Ozempic use, or on-label Wegovy use): If weight loss plateaus at under 5% total body weight after 16 weeks at 0.5 mg, escalation is reasonable. The STEP trials showed dose-response relationship up to 2.4 mg weekly (Wilding et al., New England Journal of Medicine 2021).

When NOT to escalate:

• GI side effects (nausea, vomiting, diarrhea) are still present from the last dose increase
• You're losing weight or achieving glycemic control at current dose
• You've had injection site reactions or allergic symptoms
• You're experiencing persistent reflux, gastroparesis symptoms, or severe constipation

The conservative approach: stay at the lowest effective dose. Higher doses increase side effect risk without guaranteed additional benefit.

What to do if you miss a dose (the actual FDA guidance)

The FDA label provides specific guidance based on how late you are:

If you remember within 5 days of the missed dose: Inject the missed dose as soon as you remember, then resume your regular weekly schedule.

If more than 5 days have passed: Skip the missed dose entirely. Inject your next dose on the regularly scheduled day. Do not double up.

Why the 5-day cutoff: Semaglutide has a half-life of approximately 7 days. If you inject a missed dose 6+ days late, you're overlapping with the next scheduled dose, which can cause excessive drug levels and increased side effects.

What happens if you miss multiple doses:

If you miss 2+ consecutive doses (14+ days without injection), contact your provider before resuming. You may need to restart at a lower dose to avoid severe GI side effects. The body loses some adaptation to GLP-1 agonists after 2 to 3 weeks off medication.

Pattern we see in compounded semaglutide patients:

Patients who miss doses sporadically (1 to 2 times over 6 months) usually resume without issue. Patients who miss doses regularly (every 3 to 4 weeks) rarely achieve target outcomes and have higher side effect rates when they do inject. Consistency matters more than perfection.

Compounded semaglutide administration: vial-based vs pen-based protocols

Compounded semaglutide comes in two formats: multi-dose vials requiring manual syringe draw, or prefilled pens similar to brand-name devices.

Vial-based administration (most common for compounded):

1. Supplies needed: Semaglutide vial, insulin syringes (0.3 mL or 0.5 mL with 31G or 32G needle), alcohol swabs, sharps container.

1. Draw dose:

• Clean vial top with alcohol swab
• Draw air into syringe equal to your dose volume
• Insert needle through vial stopper, inject air
• Invert vial, draw medication to prescribed volume
• Remove needle from vial, check for air bubbles (tap and push out if present)
• Confirm dose volume in syringe

1. Inject: Follow same site selection, rotation, and technique as pen-based injection above.

1. Dispose: Dispose of entire syringe in sharps container. Never reuse.

Dose volume varies by concentration:

Compounded semaglutide comes in various concentrations. Common examples:

• 2.5 mg/mL concentration: 0.5 mg dose = 0.2 mL volume
• 5 mg/mL concentration: 0.5 mg dose = 0.1 mL volume

Your provider or pharmacy will specify the volume to draw for your prescribed dose. If you're unsure, call the pharmacy. Drawing the wrong volume is a common compounded medication error.

Pen-based compounded semaglutide:

Some compounding pharmacies provide prefilled pens. Administration is identical to brand-name Ozempic pens described above.

When to call your provider about injection-site reactions

Most injection site reactions are minor and resolve within 24 to 48 hours. Some require evaluation.

Normal reactions (no action needed):

• Small red dot at injection site, fades within hours
• Mild tenderness for 12 to 24 hours
• Occasional small bruise (under 1 cm)
• Slight itching that resolves within a day

Reactions that warrant a call within 24 to 48 hours:

• Redness spreading beyond 2 inches from injection site
• Warmth, swelling, or hardness at site persisting beyond 48 hours
• Recurring large bruises (over 2 cm) at multiple injection sites
• Persistent lumps or thickened areas (possible lipohypertrophy)

Reactions requiring same-day contact:

• Severe pain at injection site
• Red streaks extending from injection site
• Fever plus injection site redness (possible infection)
• Hives or rash appearing within hours of injection

Emergency symptoms (call 911 or go to ER):

• Difficulty breathing or throat swelling after injection
• Severe abdominal pain radiating to the back (possible pancreatitis)
• Facial swelling, tongue swelling, or difficulty swallowing
• Widespread hives or anaphylaxis symptoms

True allergic reactions to semaglutide are rare (under 0.5% in clinical trials), but they do occur. Most "allergic reactions" are actually injection technique errors or reactions to needle trauma.

The decision tree for troubleshooting injection problems

If you see liquid leaking from the injection site after withdrawal: → You withdrew the needle too quickly. Next injection: hold for full 6 seconds, count slowly.

If you have a raised welt or bump immediately after injection: → You injected too shallow (intradermal). Next injection: pinch more tissue or switch to abdomen with 4 mm needle at 90 degrees.

If you have bruising after most injections: → You may be hitting small blood vessels or muscle. Next injection: avoid visible veins, ensure 90-degree angle with proper pinch, consider switching sites.

If injection is very painful: → Check three things: (1) Is medication at room temperature? (2) Did you let alcohol dry completely? (3) Are you injecting into scar tissue, moles, or previous lipohypertrophy? Address whichever applies.

If you're not seeing expected results (A1C not improving, no weight loss): → First check adherence: are you injecting every 7 days consistently? Second, check technique: are you holding for 6 seconds and rotating sites? Third, check dose: are you still at 0.25 mg (sub-therapeutic)? If all three are correct and you've been at therapeutic dose (0.5 mg+) for 12+ weeks, contact your provider about dose escalation.

If you develop persistent nausea, vomiting, or reflux: → Review the article on managing GLP-1 side effects. If symptoms persist beyond 2 weeks or interfere with daily life, contact your provider.

FAQ

How is Ozempic administered? Ozempic is administered as a once-weekly subcutaneous injection using a pre-filled pen. You attach a new needle, dial your dose, inject into abdomen, thigh, or upper arm fat at a 90-degree angle, hold for 6 seconds, then withdraw and dispose of the needle.

Where do you inject Ozempic? Inject into the abdomen (avoiding 2 inches around the navel), front/outer thigh, or back of the upper arm. All three sites have equivalent absorption. Rotate through multiple zones weekly to prevent lipohypertrophy.

Can I inject Ozempic in my arm? Yes, the back of the upper arm (triceps area) is an FDA-approved site. It may require assistance to reach. Use the same technique as abdomen or thigh injection.

How deep do you inject Ozempic? The needle should reach subcutaneous fat, typically 4 mm to 8 mm deep depending on needle length and body composition. A 4 mm needle at 90 degrees reaches the correct depth in most adults. The entire needle should be inserted under the skin.

What happens if I inject Ozempic wrong? Injecting too shallow (intradermal) causes pain, welts, and reduced absorption. Injecting too deep (intramuscular) causes faster absorption, higher side effects, and bruising. Correct technique ensures consistent therapeutic effect.

Do you pinch skin when injecting Ozempic? Yes, pinch a fold of skin and fat between thumb and forefinger before inserting the needle. This lifts subcutaneous tissue away from muscle and ensures correct injection depth. Release the pinch after needle insertion if desired, but maintain it through injection if comfortable.

How long do you hold Ozempic pen after injecting? Hold the dose button down and keep the needle in your skin for 6 full seconds after the dose counter reaches 0. This ensures complete dose delivery. Withdrawing early causes medication leakage and underdosing.

Can you reuse Ozempic needles? No. Needles dull after one use, causing more pain and tissue damage. They also risk contamination and infection. Use a new needle for every injection and dispose of used needles in a sharps container.

What size needle for Ozempic? Most adults should use 4 mm pen needles at a 90-degree angle. This reaches subcutaneous fat without hitting muscle in 99% of injection sites. Use 6 mm needles only if you have difficulty with 4 mm, or 45-degree angle if you have very low body fat.

Can I inject Ozempic cold from the fridge? You can, but cold medication stings more. Let the pen sit at room temperature for 30 minutes before injection for more comfortable administration. Once in use, Ozempic pens can be stored at room temperature (up to 86°F) for up to 56 days.

What if I see blood after Ozempic injection? A small drop of blood is normal and happens occasionally when the needle passes through a tiny blood vessel. Apply gentle pressure with a clean finger or gauze. Do not rub. If you see large amounts of blood or frequent bruising, you may be injecting too deep or hitting larger vessels.

How do you know if Ozempic pen is empty? The dose counter will not dial to your prescribed dose when the pen is nearly empty. If fewer doses remain than your prescribed amount, the counter stops at the maximum available dose. Do not try to force it. Order a refill when you have 1 to 2 doses remaining.

Can you inject Ozempic in the same spot every week? No. Injecting in the same spot causes lipohypertrophy (fat tissue buildup) within 8 to 12 weeks, which reduces absorption by 25% to 50%. Use a systematic 6-zone rotation pattern, moving at least 1 inch from the previous injection within each zone.

What happens if I miss my Ozempic injection? If you remember within 5 days, inject the missed dose immediately and resume your regular schedule. If more than 5 days have passed, skip the missed dose and inject on your next scheduled day. Do not double up.

Do you need to prime Ozempic pen every time? No. Prime the pen only before the first injection with a new pen. This removes air from the needle and confirms the pen works. For subsequent injections with the same pen, attach a new needle and inject without priming.

Sources

1. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes, Obesity and Metabolism. 2017.
3. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Mayo Clinic Proceedings. 2010.
4. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes & Metabolism. 2016.
5. Aronson R et al. Insulin pen needle design and patient preference in diabetes management. Diabetes Therapy. 2018.
6. Heise T et al. Impact of injection speed on pain and pharmacokinetics of a viscous GLP-1 analogue solution. Diabetes, Obesity and Metabolism. 2014.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
9. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Lancet Diabetes & Endocrinology. 2017.
10. Ahmann AJ et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3). Diabetes Care. 2018.
11. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7). Lancet Diabetes & Endocrinology. 2018.
12. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4). Lancet Diabetes & Endocrinology. 2017.
13. Rodbard HW et al. Oral Semaglutide Versus Subcutaneous Liraglutide and Placebo in Type 2 Diabetes (PIONEER 4). Lancet. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.